Evaluation of the frequency of BCL2 and P53 and angiogenesis in endometrial cancer and its relationship with clinicopathological characteristics

P53 is mutated in more than 50% of solid tumors and has been changed in 30-40% of endometrial cancer which is the most common malignancy of the genital tract of women and this change is associated with papillary serous cell type and advanced stage and poor prognosis. In addition، the overexpression of BCL2 and tumor angiogenesis is important in the prognosis of patient. Therefore، this study was performed with aim to evaluate the expression of BCL2 and P53 and angiogenesis in endometrial cancer and its relationship with clinicopathological characteristics and the factors affecting the prognosis of disease.

In this retrospective longitudinal study which was performed during 2005-2014، 30 files of patients with endometrial cancer in three different hospitals (Imam Reza، Ghaem، Omid) were collected. The pathology samples were immunohistochemical staining in terms of Bcl2 and P53 markers and angiogenesis and the association of these markers with factors affecting the prognosis and recurrence of disease were investigated. Log rank، t-test and Chi-square tests were used to analyze the data and P.

P53 expression was positive in 9 cases of 10 patients (90%) with non-endometrial cancer and all patients (100%) were negative in terms of Bcl2 and angiogenesis was severe in 8 cases of 10 patients (80%) with non-endometrial cancer and in 6 cases of 20 patients (30%) with endometrial cancer. There was significant relation between tumor histology and tumor grade and stage of the disease and survival (P = 0. 002).

Since there is relationship between genetic markers with stage and grade of disease and also survival of the patients، it is better that the related block be evaluated in terms of these markers at the time of pathological diagnosis of endometrial cancer.